Septerna, Inc. (SEPN): EBITDA
-$66.70M
Year ended 2025-12-31
-$71.79M
Trailing 12 months to 2026-09-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$66.70M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$79.42M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $2.88M | n/a | 2025-03-27, From 2023-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Septerna, Inc. (SEPN) | 2025-12-31 | -$66.70M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | -$156.85M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$70.50M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $1.35M | n/m |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | -$2.41M | n/m |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$40.44M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.70M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$48.29M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$11.21M | n/m |
Compare SEPN, PTGX, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗